To test if the FFL (PDGF/FLT1/SHC1) is associated with clinical outcomes, we conducted survival analysis of patients with luminal A breast cancer and PICK3CA mutation (Kaplan–Meier plots and log-rank tests) by comparing patients with the FFL (PDGF/FLT1/SHC1) (n = 100) and those without the FFL (PDGF/FLT1/SHC1) (n = 37). This evidence concerns the gene SHC1 and breast carcinoma.